SG11201810220XA - Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal - Google Patents
Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammalInfo
- Publication number
- SG11201810220XA SG11201810220XA SG11201810220XA SG11201810220XA SG11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA SG 11201810220X A SG11201810220X A SG 11201810220XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nutritional composition
- rule
- mammal
- probiotic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pediatric Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177649 | 2016-07-01 | ||
| PCT/EP2017/066161 WO2018002240A1 (fr) | 2016-07-01 | 2017-06-29 | Composition nutritionnelle comprenant un probiotique pour le traitement prophylactique et/ou thérapeutique de troubles de l'anxiété et d'états associés chez un mammifère |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810220XA true SG11201810220XA (en) | 2018-12-28 |
Family
ID=56321833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809593YA SG11201809593YA (en) | 2016-07-01 | 2017-06-29 | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal |
| SG11201810220XA SG11201810220XA (en) | 2016-07-01 | 2017-06-29 | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809593YA SG11201809593YA (en) | 2016-07-01 | 2017-06-29 | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP3478305A1 (fr) |
| CN (2) | CN109310716A (fr) |
| BR (2) | BR112018075625A2 (fr) |
| CA (2) | CA3023166A1 (fr) |
| ES (1) | ES2969755T3 (fr) |
| MX (2) | MX2018014798A (fr) |
| PH (2) | PH12018502300A1 (fr) |
| SG (2) | SG11201809593YA (fr) |
| WO (2) | WO2018002240A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7154473B2 (ja) * | 2017-05-31 | 2022-10-18 | 学校法人順天堂 | 疲労回復用および／または疲労蓄積予防用組成物 |
| CA3065903C (fr) * | 2017-06-02 | 2023-01-24 | University Of Otago | Utilisation de bacteries d'acide lactique permettant de traiter ou prevenir la depression postnatale et/ou l'anxiete postnatale |
| WO2019141465A1 (fr) * | 2018-01-18 | 2019-07-25 | Dupont Nutrition Biosciences Aps | Probiotiques pour la santé mentale et cognitive |
| EP4147704A1 (fr) | 2018-01-29 | 2023-03-15 | PrecisionBiotics Group Limited | Bifidobacterium longum ncimbb41-616 |
| US11400123B2 (en) | 2018-01-29 | 2022-08-02 | Precisionbiotics Group Limited | Combination product for prophylaxis and treatment of irritable bowel syndrome |
| EP3746098A1 (fr) | 2018-01-29 | 2020-12-09 | PrecisionBiotics Group Limited | Bifidobactérium longum |
| JP2020039308A (ja) * | 2018-09-12 | 2020-03-19 | キリンホールディングス株式会社 | 労働パフォーマンスの向上用組成物 |
| ES2763350B2 (es) * | 2018-11-28 | 2020-10-13 | Consejo Superior Investigacion | Cepa de christensenella minuta y uso de la misma |
| JP7406325B2 (ja) * | 2019-08-08 | 2023-12-27 | 森永乳業株式会社 | 分離不安障害の予防又は改善のための組成物 |
| IT202000008482A1 (it) * | 2020-04-21 | 2021-10-21 | Montefarmaco Otc S P A | Composizione orale contente s-adenosil metionina (same) e almeno un probiotico e suo uso |
| CN114098084A (zh) * | 2021-04-13 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种缓解长期低剂量辐射暴露所致认知损伤的益生菌组合物及其应用 |
| CN113288918B (zh) * | 2021-06-23 | 2022-11-08 | 中南大学 | 益生菌在制备治疗孕期应激对子代损伤药物的应用 |
| MX2024006254A (es) * | 2021-12-16 | 2024-08-20 | Biopolis S L | Uso de postbioticos en el tratamiento y/o prevencion de los trastornos de ansiedad. |
| CN116076734B (zh) * | 2022-10-26 | 2024-04-26 | 健码制药（广东）有限公司 | 一种抗氧化和抗抑郁的中药/益生菌/益生元微生态制剂及其制备与应用 |
| CN116138457A (zh) * | 2022-12-14 | 2023-05-23 | 温州医科大学 | 一种具有缓解抑郁样症状作用的复合营养组合物 |
| CN117143760B (zh) * | 2023-07-12 | 2024-09-20 | 西南大学 | 一株能促进5-htp分泌及缓解抑郁的鼠李糖乳酪杆菌ky16及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0700552A2 (en) * | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
| EP2110028A1 (fr) * | 2008-04-15 | 2009-10-21 | Nestec S.A. | Expression de BDNF hippocampique et de Bifidobacterium longum |
| RU2642301C9 (ru) * | 2008-11-03 | 2018-06-27 | Нестек С.А. | Пробиотический бактериальный штамм для получения питательной композиции, улучшающей характер сна |
| AU2011351420A1 (en) * | 2010-12-29 | 2013-07-18 | Nestec S.A. | Fiber and probiotics for reducing intestinal symptoms related to chronic stress |
| CN103415297A (zh) * | 2010-12-29 | 2013-11-27 | 雀巢产品技术援助有限公司 | 用于减少压力相关肠症状的包含纤维和益生菌的营养组合物 |
| EP2609814A1 (fr) * | 2011-12-30 | 2013-07-03 | Nestec S.A. | Lactobacillus reuteri DSM 17938 pour le développement de la fonction cognitive |
| AU2014363470B2 (en) * | 2013-12-13 | 2018-09-06 | Société des Produits Nestlé S.A. | Use of a modified sweet whey and a modified sweet whey containing infant formula for promoting the postnatal development of the infant central nervous system and related cognitive functions |
| US20150305384A1 (en) * | 2014-04-25 | 2015-10-29 | Mead Johnson Nutrition Company | Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics |
| US20160058808A1 (en) * | 2014-09-03 | 2016-03-03 | California Institute Of Technology | Microbe-based modulation of serotonin biosynthesis |
-
2017
- 2017-06-29 BR BR112018075625-3A patent/BR112018075625A2/pt unknown
- 2017-06-29 CN CN201780036768.6A patent/CN109310716A/zh active Pending
- 2017-06-29 ES ES17732952T patent/ES2969755T3/es active Active
- 2017-06-29 MX MX2018014798A patent/MX2018014798A/es unknown
- 2017-06-29 EP EP17732481.1A patent/EP3478305A1/fr active Pending
- 2017-06-29 CA CA3023166A patent/CA3023166A1/fr active Pending
- 2017-06-29 EP EP17732952.1A patent/EP3478306B1/fr active Active
- 2017-06-29 BR BR112018074867-6A patent/BR112018074867A2/pt unknown
- 2017-06-29 CA CA3029145A patent/CA3029145A1/fr active Pending
- 2017-06-29 CN CN201780038385.2A patent/CN109310717A/zh active Pending
- 2017-06-29 MX MX2018014559A patent/MX2018014559A/es unknown
- 2017-06-29 SG SG11201809593YA patent/SG11201809593YA/en unknown
- 2017-06-29 WO PCT/EP2017/066161 patent/WO2018002240A1/fr unknown
- 2017-06-29 SG SG11201810220XA patent/SG11201810220XA/en unknown
- 2017-06-29 WO PCT/EP2017/066158 patent/WO2018002238A1/fr unknown
-
2018
- 2018-10-30 PH PH12018502300A patent/PH12018502300A1/en unknown
- 2018-11-15 PH PH12018502406A patent/PH12018502406A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018075625A2 (pt) | 2019-03-19 |
| WO2018002240A1 (fr) | 2018-01-04 |
| EP3478306A1 (fr) | 2019-05-08 |
| CN109310716A (zh) | 2019-02-05 |
| CA3023166A1 (fr) | 2018-01-04 |
| PH12018502300A1 (en) | 2019-09-23 |
| CN109310717A (zh) | 2019-02-05 |
| SG11201809593YA (en) | 2018-11-29 |
| BR112018074867A2 (pt) | 2019-03-06 |
| CA3029145A1 (fr) | 2018-01-04 |
| MX2018014559A (es) | 2019-03-28 |
| ES2969755T3 (es) | 2024-05-22 |
| WO2018002238A1 (fr) | 2018-01-04 |
| PH12018502406A1 (en) | 2019-09-30 |
| MX2018014798A (es) | 2019-04-29 |
| EP3478306B1 (fr) | 2023-11-01 |
| EP3478305A1 (fr) | 2019-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810220XA (en) | Nutritional composition comprising a probiotic for the prevention and/or treatment of anxiety disorders and related conditions in a mammal | |
| SG11201810117WA (en) | Human platelet lysate derived extracellular vesicles for use in medicine | |
| SG11201811227QA (en) | Method for facilitating maturation of the mammalian immune system | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201807195VA (en) | Compositions comprising bacterial blautia strains for treating visceral hypersensitivity | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201807811RA (en) | Food compositions for weaning | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809172WA (en) | Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201806057QA (en) | Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201803338VA (en) | Culinary seasoning or bouillon tablet | |
| SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
| SG11201807963WA (en) | Compositions useful in the prevention and/or treatment of disorders of the oral cavity, upper airways and esophagus | |
| SG11201806545WA (en) | Compositions comprising fatty acids and their use | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| SG11201811311VA (en) | Compounds for imaging tau protein aggregates |